JP2023524873A5 - - Google Patents
Info
- Publication number
- JP2023524873A5 JP2023524873A5 JP2022568552A JP2022568552A JP2023524873A5 JP 2023524873 A5 JP2023524873 A5 JP 2023524873A5 JP 2022568552 A JP2022568552 A JP 2022568552A JP 2022568552 A JP2022568552 A JP 2022568552A JP 2023524873 A5 JP2023524873 A5 JP 2023524873A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cells
- motif
- nucleic acid
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2007044.7 | 2020-05-13 | ||
| GBGB2007044.7A GB202007044D0 (en) | 2020-05-13 | 2020-05-13 | Method |
| PCT/GB2021/051134 WO2021229218A1 (en) | 2020-05-13 | 2021-05-12 | Method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524873A JP2023524873A (ja) | 2023-06-13 |
| JP2023524873A5 true JP2023524873A5 (https=) | 2024-03-26 |
Family
ID=71134932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568552A Withdrawn JP2023524873A (ja) | 2020-05-13 | 2021-05-12 | 方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230256093A1 (https=) |
| EP (1) | EP4149523A1 (https=) |
| JP (1) | JP2023524873A (https=) |
| CN (1) | CN115551543A (https=) |
| AU (1) | AU2021269889A1 (https=) |
| CA (1) | CA3178239A1 (https=) |
| GB (1) | GB202007044D0 (https=) |
| WO (1) | WO2021229218A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201509413D0 (en) * | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| WO2023139360A1 (en) * | 2022-01-19 | 2023-07-27 | Autolus Limited | Nucleic acid construct |
| CN118109416B (zh) * | 2023-03-30 | 2024-11-22 | 广州百吉生物制药有限公司 | 功能增强型工程化免疫细胞及其制备和应用 |
| IT202300011250A1 (it) * | 2023-06-01 | 2024-12-01 | Ospedale Pediatrico Bambino Gesù | Cellule effettrici di recettore antigenico chimerico specifico per gd2 per l'uso nel trattamento di tumori solidi, eventualmente in combinazione con inibitori del potenziatore di zeste omologo 2 (ezh2) |
| GB202401216D0 (en) | 2024-01-30 | 2024-03-13 | Cambridge Entpr Ltd | Engineered lymphocytes |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9908807D0 (en) | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| MX373687B (es) | 2013-11-21 | 2020-07-07 | Ucl Business Ltd | Célula natural (nk) |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| WO2016126608A1 (en) * | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201507108D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| GB201509413D0 (en) | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201702617D0 (en) * | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| GB201812474D0 (en) * | 2018-07-31 | 2018-09-12 | Autolus Ltd | Nucleic acid construct |
-
2020
- 2020-05-13 GB GBGB2007044.7A patent/GB202007044D0/en not_active Ceased
-
2021
- 2021-05-12 CA CA3178239A patent/CA3178239A1/en active Pending
- 2021-05-12 WO PCT/GB2021/051134 patent/WO2021229218A1/en not_active Ceased
- 2021-05-12 AU AU2021269889A patent/AU2021269889A1/en active Pending
- 2021-05-12 JP JP2022568552A patent/JP2023524873A/ja not_active Withdrawn
- 2021-05-12 US US17/924,345 patent/US20230256093A1/en active Pending
- 2021-05-12 EP EP21730976.4A patent/EP4149523A1/en active Pending
- 2021-05-12 CN CN202180034811.1A patent/CN115551543A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023524873A5 (https=) | ||
| JP7745616B2 (ja) | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 | |
| CN111018986B (zh) | 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用 | |
| JP2023053110A (ja) | キメラ抗原受容体、組成物及び方法 | |
| CN110869046A (zh) | 通用型抗cd22嵌合抗原受体工程化的免疫细胞 | |
| CN104592391B (zh) | 一种双特异性抗体EpCAM×CD3的构建及应用 | |
| KR20180083868A (ko) | 종양 형질도입용 조성물 및 방법 | |
| CN113784980A (zh) | 人源化抗Claudin18.2嵌合抗原受体及其用途 | |
| KR20220144888A (ko) | 최적화된 다기능 t 세포를 포함하는 키메라 수용체 t 세포를 사용하는 치료 | |
| JP2024525492A5 (https=) | ||
| CN104829725A (zh) | 一种双特异性抗体cd133×cd3的构建及应用 | |
| JP7747724B2 (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 | |
| JP2022525925A5 (https=) | ||
| CN114929863B (zh) | 共表达趋化因子受体的免疫效应细胞 | |
| JP2023524873A (ja) | 方法 | |
| TW202227616A (zh) | 分離ｃｄ８＋選擇ｔ細胞的方法 | |
| CN119968397A (zh) | 特异性结合gpc3的嵌合抗原受体及其应用 | |
| TW202003049A (zh) | 結合至階段特異性胚胎抗原4 (ssea4)之嵌合抗原受體及其用途 | |
| WO2021259334A1 (zh) | 自我调节型嵌合抗原受体及其在肿瘤免疫中的应用 | |
| CN121969385A (zh) | 含有il-2变体以增强car t细胞的功能性的car-衔接子 | |
| JP2022543060A5 (https=) | ||
| WO2017028634A1 (zh) | 一种抗体融合蛋白及其制备方法与应用 | |
| WO2023076811A1 (en) | Combination therapies with chimeric antigen receptors | |
| CN116783288A (zh) | 用于cd70定向癌症免疫疗法的基因修饰的自然杀伤细胞 | |
| CN116239690B (zh) | 一种抗cd123的纳米抗体及其制备方法和应用 |